BioElectronics Analyst Brief: Beyond the Traditional Therapies by Small Cap Traders

Oct 20, 2014, 07:30 ET from Small Cap Traders

NEW YORK, Oct 20, 2014 /PRNewswire/ -- There can be no doubt that the market for pain relief products will continue to grow, regardless of the economic climate. As the massive baby boomer population ages their aches and pains will follow them and the affordable Care act should make more funding available to spend on pain relief products. As the population becomes more health aware, the use of oral pain medications like aspirin is being questioned and too often topical analgesics don't provide the desired effect. Electronic stimulation of inflamed tissue seems to be a viable alternative that has yet to be fully embraced in the medical community or the general population.

BioElectronics Corporation (OTCBB: BIEL), a development stage company, is engaged in the manufacturing of inexpensive, drug-free, anti-inflammatory medical devices and patches. Its Products include Testimonials, ActiPatch, Allay, Smart Insole and RecoveryRx. The underlying concept of the BIEL product line is to replace the short duration, high power treatments which can only be obtained in the clinic by a trained professional, with an easy to use, self-administered, very low power device that can be used 24 hours per day.

BIEL has good, effective products available, yet the marketplace is inundated with competing electronic pain relief products. The company is working to create brand awareness for their superior products, a process that takes time. Investors willing to take a chance on a development stage company in the burgeoning health care market should be looking at BioElectronics Corp.

An analyst brief which covers a brief technical analysis and analyst recommendation can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:

Copy and paste to browser may be required.

About Small Cap Traders

Once you have read our reports written by financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties.

3rd party financial analysts provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Forward-Looking Disclaimer   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Compliance Procedure   

Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the analyst report.

If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at For any urgent concerns or inquiries please contact us at


SOURCE Small Cap Traders